[go: up one dir, main page]

NI201900004A - Composición vaginal comprendiendo una combinación de estrógeno y vitamina d. - Google Patents

Composición vaginal comprendiendo una combinación de estrógeno y vitamina d.

Info

Publication number
NI201900004A
NI201900004A NI201900004A NI201900004A NI201900004A NI 201900004 A NI201900004 A NI 201900004A NI 201900004 A NI201900004 A NI 201900004A NI 201900004 A NI201900004 A NI 201900004A NI 201900004 A NI201900004 A NI 201900004A
Authority
NI
Nicaragua
Prior art keywords
vitamin
estrogen
combination
composition including
vaginal composition
Prior art date
Application number
NI201900004A
Other languages
English (en)
Inventor
Colli Enrico
F Archer David
Original Assignee
Chemo Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Res S L filed Critical Chemo Res S L
Publication of NI201900004A publication Critical patent/NI201900004A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición vaginal que comprende una combinación de estrógeno y vitamina D o un análogo de vitamina D a una administración de dosificación diaria de (i) estrógeno que varía de 1 µg a 100 µg de estrógeno de equivalente de estradiol y (ii) vitamina D o análogo que varía de 7,5 µg a 100 µg de vitamina D equivalente.
NI201900004A 2016-07-22 2019-01-18 Composición vaginal comprendiendo una combinación de estrógeno y vitamina d. NI201900004A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305941.3A EP3272333A1 (en) 2016-07-22 2016-07-22 Vaginal composition comprising a combination of estrogen and vitamin d

Publications (1)

Publication Number Publication Date
NI201900004A true NI201900004A (es) 2019-04-29

Family

ID=56561320

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900004A NI201900004A (es) 2016-07-22 2019-01-18 Composición vaginal comprendiendo una combinación de estrógeno y vitamina d.

Country Status (10)

Country Link
US (2) US20190224213A1 (es)
EP (2) EP3272333A1 (es)
BR (1) BR112019001207A2 (es)
CL (1) CL2019000174A1 (es)
CO (1) CO2019000604A2 (es)
CR (1) CR20190026A (es)
MX (1) MX390231B (es)
NI (1) NI201900004A (es)
PH (1) PH12019500137A1 (es)
WO (1) WO2018015503A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP3787659A1 (en) * 2018-05-04 2021-03-10 The Procter & Gamble Company Compositions and methods for treating vaginal atrophy
WO2019213473A1 (en) 2018-05-04 2019-11-07 The Procter & Gamble Company Compositions and methods for treating vaginal dryness
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
EP4066824A1 (en) * 2021-03-31 2022-10-05 Dompe' Farmaceutici S.P.A. Combination therapy for covid-19 vaccination

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062715A (en) 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5514698A (en) 1994-03-21 1996-05-07 Ortho Pharmaceutical Corporation Antifungal vaginal cream composition
JP3705620B2 (ja) 1994-12-28 2005-10-12 帝国臓器製薬株式会社 経粘膜投与用製剤
EP0889724A1 (en) 1996-02-27 1999-01-13 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
DE19608423A1 (de) 1996-03-05 1997-09-11 Merck Patent Gmbh Implantate mit phasenweiser Arzneistoffabgabe
IL123813A0 (en) 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
US6197327B1 (en) 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6905701B2 (en) 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US20040043071A1 (en) 2002-06-21 2004-03-04 Pauletti Giovanni M. Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs
FR2766710B1 (fr) 1997-08-04 1999-10-29 Inst Pharma De Rech Applic Et Composition pharmaceutique, comprime forme a partir de celle-ci et son utilisation comme antiseptique vaginal a action prolongee
DE19916419B4 (de) 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
ATE532521T1 (de) * 2000-12-15 2011-11-15 Novo Nordisk Femcare Ag Verwendung eines östrogens bei der herstellung einer östrogenhaltigen zusammensetzung zur behandlung von atrophischer vaginitis
US7004171B2 (en) 2002-02-25 2006-02-28 Hi-Gienic Intra Vaginal Technologies Ltd. System for transvaginal drug delivery
WO2004103232A1 (en) 2003-05-15 2004-12-02 Apothecus Pharmaceutical Corp. Dissolvable vaginal deodorizing films and methods of vaginal deodorizing utilizing pliable dissolvable film
WO2005016321A1 (en) 2003-08-15 2005-02-24 Qlt Usa, Inc. Adhesive bioerodible transmucosal drug delivery system
US20050070501A1 (en) 2003-09-29 2005-03-31 New York Blood Center, Inc. Water dispersible film
US20060040904A1 (en) 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
ATE540684T1 (de) 2005-04-27 2012-01-15 Shenzhen Phlora Biotechnology Ltd Zubereitung und verfahren zur regulierung und aufrechterhaltung der vaginalen bakterienflora und der normalen acidität in der vagina
CA2640432A1 (en) 2006-01-27 2007-08-09 Duramed Pharmaceuticals, Inc. Regimens for treatment of conditions related to estrogen deficiency
CA2687310A1 (en) 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
US20080312198A1 (en) 2007-06-14 2008-12-18 Rodriguez Gustavo C Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound
DK2456421T3 (en) 2009-07-21 2017-06-06 The Population Council Inc VAGINAL RING consisting of multiple layers with gradient
CA2808276A1 (en) 2010-08-20 2012-02-23 Teva Women's Health, Inc. Intravaginal devices, methods of making, and uses thereof
CN102641548B (zh) 2011-02-18 2016-08-03 帕洛阿尔托研究中心公司 包括化学品渗透增强剂的透粘膜药物输送装置和方法
KR101785414B1 (ko) 2011-12-29 2017-10-16 라보라토리오스 안드로마코 에스.에이. 여성에서 연속 사용 피임제로서 사용될 수 있는, 멜록시캄 및 유효 성분 방출 조절제를 포함하는 질 고리
WO2013098592A1 (es) 2011-12-29 2013-07-04 Universidad De Chile Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia
ITMI20120867A1 (it) 2012-05-18 2013-11-19 Labomar S R L Composizione per il trattamento di lesioni.
FR3018193B1 (fr) 2014-03-10 2017-09-08 Probionov Comprime vaginal muco-adhesif a liberation prolongee
CN107073019B (zh) * 2014-03-13 2020-04-17 深圳优丽康生物技术有限公司 一种阴道用组合物与该组合物的用途
WO2016054002A1 (en) 2014-09-29 2016-04-07 Yale University Progesterone impregnated vaginal ring/pessary

Also Published As

Publication number Publication date
CL2019000174A1 (es) 2019-06-28
EP3487478A1 (en) 2019-05-29
PH12019500137A1 (en) 2019-07-29
CO2019000604A2 (es) 2019-05-21
CR20190026A (es) 2019-04-09
MX390231B (es) 2025-03-20
US20210069210A1 (en) 2021-03-11
MX2019000806A (es) 2019-06-20
US20190224213A1 (en) 2019-07-25
BR112019001207A2 (pt) 2019-04-30
US11590145B2 (en) 2023-02-28
EP3272333A1 (en) 2018-01-24
WO2018015503A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
NI201900004A (es) Composición vaginal comprendiendo una combinación de estrógeno y vitamina d.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CO2021001061A2 (es) Composición y método para tratar el dolor
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
MX372914B (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
PE20230607A1 (es) Composicion de cannabis
NZ726746A (en) Stable cannabinoid formulations
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MX2017001512A (es) Compuestos activos hacia bromodominios.
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
WO2020044119A3 (en) Oral formulations of lavender and cannabinoids
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CR20150007A (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
GEAP202215306A (en) Formulations of copanlisib
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX394047B (es) Una composición que comprende una combinación de extracto de schinus terebinthifolius y cafeína.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
CL2018002368A1 (es) Formulaciones de oritavancina
CO2017004809A2 (es) Composiciones de triptamidas